BGLC

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

Wall Street analysts forecast BGLC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BGLC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioNexus Gene Lab Corp revenue for the last quarter amounts to 2.54M USD, decreased -3.29 % YoY.

BioNexus Gene Lab Corp. EPS for the last quarter amounts to -0.39 USD, decreased -48.00 % YoY.

BioNexus Gene Lab Corp (BGLC) has 30 emplpoyees as of December 16 2025.

Today BGLC has the market capitalization of 9.79M USD.